UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material under §240.14a-12
|
Silexion Therapeutics Corp
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
☒
|
No fee required.
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11
|
On April 28, 2026, Silexion Therapeutics Corp issued the following announcement:
SILEXION ANNOUNCES ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING TO MAY 5, 2026
Grand Cayman, Cayman Islands, April 28, 2026 - Silexion Therapeutics Corp (Nasdaq: SLXN) (“Silexion” or the “Company”) announced today that
the extraordinary general meeting of the Company (the “Extraordinary Meeting”), scheduled to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on April 28,
2026, was convened and then adjourned for one week without conducting any business, and will reconvene at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on May 5, 2026 at the offices of the Company’s external legal counsel, Meitar Law Offices,
16 Abba Hillel Road, 10th floor, Ramat Gan, Israel 5250608. The Extraordinary Meeting may also be attended (and questions may be submitted, but shareholders may not speak or vote by attending in that way) via live webcast at https://www.cstproxy.com/silexion/secondegm2026,
or by calling 1-800-450-7155 (toll-free, within the U.S. and Canada) or +1 857-999-9155 (outside of the U.S. and Canada- standard rates apply), conference ID 8161245#.
The Extraordinary Meeting is being held for the purpose of presenting three proposals for approval:
Proposal 1 - Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by 50,000,000 ordinary shares, from US$121,500 divided into
9,000,000 ordinary shares of a par value of US$0.0135 each (which is our current authorized share capital), to US$796,500 divided into 59,000,000 ordinary shares of a par value of US$0.0135 each (the “Authorized Share
Capital Increase Proposal”).
Proposal 2 - Equity Incentive Plan Evergreen Increase Proposal: An amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the “2024
Plan”), effective as of January 1, 2026, that increases the maximum number of ordinary shares added annually on January 1st under the “evergreen” provision of Section 5(b)(i) of the 2024 Plan (unless a lesser increase is set by the Company’s
board of directors (the “Board”) for the relevant upcoming year) from (i) 5% of the Company’s issued and outstanding ordinary shares as of January 1st, to (ii) such number of ordinary shares as yields a pool of
ordinary shares reserved under all equity incentive plans of the Company that constitutes, in the aggregate, 10% of the issued and outstanding ordinary shares on a fully diluted basis (the “Evergreen Increase Proposal”).
Proposal 3 - Reverse Share Split Proposal: Authorization of the Board to effect a reverse share split of our ordinary shares, par value $0.0135 per share (“ordinary shares”) at a ratio of not less than 1-for-4 and not more than 1-for-10, with the actual ratio to be determined by the Board prior to the Extraordinary Meeting and to be presented for approval by the
Company’s shareholders at the Extraordinary Meeting (the “Reverse Share Split Proposal”).
Each of the above proposals is described in the notice and definitive proxy statement related to the Extraordinary Meeting filed by the Company with the Securities and Exchange Commission (the “SEC”) under cover of Schedule 14A on April 9, 2026 (collectively, the “Definitive Proxy Statement”).
The Authorized Share Capital Increase Proposal is intended to enable Silexion to maintain compliance with Nasdaq Listing Rule 5550(b)(1), which requires that Silexion have at least $2.5 million of shareholders’ equity
under the Equity Standard of the Nasdaq Capital Market, on which its ordinary shares and warrants are listed. Sielxion’s issuance of equity securities in value-enhancing transactions, whether extraordinary or ordinary-course, will serve as the
primary means by which it can effectively achieve that goal, and for that, it will need additional authorized share capital. Silexion also requires the increased share capital for the basic financing needs of its operations and potential business
development transactions, in keeping with its goal of creating substantive value for its shareholders. As Silexion navigates the upcoming critical period in the clinical development of its innovative RNA interference (RNAi) therapies to treat solid
tumors driven by KRAS mutations, it will need both sufficient funding and transactional flexibility for that development process. An enhanced authorized share capital will provide it with that requisite flexibility.
The Evergreen Increase Proposal is aimed at ensuring that Silexion has a sufficient number of ordinary shares available on an ongoing basis to provide equity incentives to employees, officers and directors in amounts
determined appropriate by Silexion’s compensation committee, board of directors and management. Silexion’s issued and outstanding share capital is dynamic, given the large number of financing and other transactions that the Company needs to effect
relatively frequently to meet its basic operating needs. That, in turn, mandates that at the start of each year, Silexion has a sufficiently large increase to the reserve under the 2024 Plan via the “evergreen” mechanism to enable it to adequately
incentivize employees, officers and directors in a customary manner that takes into account the expected increase in issued and outstanding share capital in that upcoming year. The proposed “evergreen” increase would furthermore conform with the
customary limit on dilution to shareholders from equity incentive compensation that is supported by institutional shareholder groups.
The Reverse Share Split Proposal is intended to enable the Company to maintain its compliance with Nasdaq Listing Rule 5550(a)(2), which requires that the ordinary shares maintain a minimum bid price of $1.00 per share
on an ongoing basis in order to remain listed on the Nasdaq Capital Market. While the Company is presently in compliance with the minimum bid price requirement, the Company seeks to protect its Nasdaq listing and to preemptively prevent any potential
deficiency as to that requirement, given that the closing price of the ordinary shares in recent times has been only slightly above or below the minimum level. Based on market conditions and the market price of the ordinary shares immediately prior
to the reconvening of the Extraordinary Meeting, the Board will determine and present the intended reverse split ratio at the reconvened Extraordinary Meeting.
The record date for the Extraordinary Meeting remains the close of business on April 7, 2026. Shareholders who have not submitted their proxy for the Extraordinary Meeting, or who wish to change their proxy, are urged to
do so promptly. Shareholders who have previously submitted their proxy and do not wish to change their proxy need not take any action. If you are a shareholder and have questions or need assistance voting your shares, please contact our proxy
solicitor, Alliance Advisors, toll-free at 1-866-206-7359 (from the United States and Canada) or 1-551-368-0031 (from other locations), or by e-mail to SLXN@allianceadvisors.com.
Further information related to attendance, voting and the proposals to be considered at the reconvened Extraordinary Meeting is provided in the Definitive Proxy Statement, as supplemented by the supplemental information
provided by the Company in this announcement, which is being filed with the SEC under cover of Schedule 14A on April 28, 2026 (this “Proxy Supplement”).
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common
oncogenic driver in human cancers. The Company’s first-generation product, LODER™, showed promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is currently advancing its next-generation, lead siRNA candidate, SIL204,
designed to target a broader range of KRAS mutations, which has shown significant potential in preclinical studies, towards clinical trials in Israel and the European Union. The Company remains committed to pushing the boundaries of therapeutic
innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the U.S. federal securities laws. All statements other than statements of historical fact contained in this communication, including statements
regarding Silexion’s business strategy, listing on Nasdaq, compliance with Nasdaq Listing Rules, and prospective capital raising activities, are forward-looking statements. Forward-looking statements involve a number of risks, uncertainties, and
assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's strategy, future operations,
financial position, projected costs, prospects, and plans; (ii) the impact of the regulatory environment and compliance complexities; (iii) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain
additional capital; (iv) Silexion’s ability to maintain its Nasdaq listing and maintain compliance with all Nasdaq Listing Rules; and (v) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the
Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026 (the “2025 Annual Report”). Silexion cautions you against placing undue reliance on
forward-looking statements, which reflect current beliefs, are based on information currently available, and which speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future
events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Additional Information and Where to Find It
The Definitive Proxy Statement has been mailed to the Company’s shareholders of record as of the record date for the Extraordinary Meeting. Investors and security holders of the Company are advised to read the Definitive
Proxy Statement, as updated by this Proxy Supplement, as well as the 2025 Annual Report, because they contain important information about the Extraordinary Meeting and the Company. Investors and security holders of the Company may also obtain a copy
of the Definitive Proxy Statement, this Proxy Supplement, the 2025 Annual Report, and other relevant documents that have been or will be filed by the Company with the SEC, without charge and once available, at the SEC’s website at www.sec.gov or by
directing a request to: Mirit Horenshtein Hadar, the Company’s Chief Financial Officer and Secretary, by calling +972-3-756-4986, or by emailing mirit@silexion.com.
Participants in the Solicitation
The Company and certain of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in respect of the proposals to be
considered and voted on at the Extraordinary Meeting. Information concerning the interests (if any) of the directors and executive officers of the Company is set forth in the Definitive Proxy Statement, which may be obtained free of charge from the
sources indicated below.
Contacts
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets and IR Contact
ARX Capital Markets
North American Equities Desk
silexion@arxadvisory.com
Proxy Solicitor
Alliance Advisors
1-866-206-7359 (in the United States)
1-551-368-0031 (outside of the United States)
e-mail: SLXN@allianceadvisors.com